### 3Q17 FINANCIALS

<table>
<thead>
<tr>
<th>Financials</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Product Revenue</td>
<td>$6.40B</td>
</tr>
<tr>
<td>YTD</td>
<td>$19.83B</td>
</tr>
<tr>
<td>Non-GAAP EPS</td>
<td>$2.27</td>
</tr>
<tr>
<td>YTD</td>
<td>$7.06</td>
</tr>
<tr>
<td>Operating Cash Flow</td>
<td>$2.69B</td>
</tr>
<tr>
<td>YTD</td>
<td>$9.15B</td>
</tr>
</tbody>
</table>

### SELECTED PIPELINE PRODUCT CANDIDATES

#### HIV
- **B/F/TAF**
  - Potential Indications: HIV/AIDS
  - U.S. and EU Regulatory Submission

- **Descovy**
  - Potential Indications: PrEP

#### Liver Diseases
- **Selonsertib**
  - Potential Indications: NASH

- **GS-9674**
  - Potential Indications: NASH, Primary Biliary Cirrhosis, Primary Sclerosing Cholangitis

- **GS-0976**
  - Potential Indications: NASH

#### Hematology / Oncology
- **Axicabtagene ciloleucel**
  - Potential Indications: DLBCL, PMBCL & TFL
  - EU Regulatory Submission

- **KTE-C19**
  - Potential Indications: Adult ALL, Pediatric ALL, Indolent NHL, MCL

- **KITE-585 (anti-BCMA)**
  - Potential Indications: MM

- **KITE-718 (MAGE A3/A6)**
  - Potential Indications: Solid Tumor

- **Andecaliximab (MMP9 mAb inhibitor)**
  - Potential Indications: Gastric Cancer

#### Inflammation / Respiratory
- **Filgotinib**
  - Potential Indications: Rheumatoid Arthritis, Crohn’s Disease, Ulcerative Colitis

### COMMERCIAL PORTFOLIO HIGHLIGHTS

#### Human Immunodeficiency Virus (HIV)
- **Genvoya**
  - elvitegravir 50mg/cobicistat 50mg/tenofovir alafenamide 150mg tablets

- **Odefsey**
  - emtricitabine 200mg/tenofovir 300mg tablets
  - odefsey 200mg/tenofovir 300mg/tenofovir alafenamide 150mg tablets

- **Descovy**
  - emtricitabine 200mg/tenofovir 250mg/tenofovir alafenamide 25mg tablets

#### Hematitis C Virus (HCV)

- **SOVALDI**
  - sofosbuvir 400mg tablets

- **HARVONI**
  - ledipasvir/sofosbuvir 90mg/400mg tablets

- **CLOLUSA**
  - ledipasvir/sofosbuvir/valvira 90mg/400mg/100mg tablets

- **VOSUVI**
  - asunaprevir 400mg/velpatasvir 100mg tablets

**Hepatitis B Virus (HBV)**

**Oncology**

- **YESCARTA**
  - axelimab-dpc (axicabtagene ciloleucel)

### Analyst Coverage

Argus, Atlantic Equities, Baird, BofA Merrill Lynch, Barclays, BMO, Citi, Cowen & Company, Credit Suisse, Deutsche Bank, Evercore ISI, Goldman Sachs, Guggenheim Securities, Jefferies, JPMorgan, Leerink Partners, Maxim Group, Mizuho, Morgan Stanley, Morningstar, Needham, RBC, Standard and Poor, UBS, Wells Fargo